Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Non-Current Deffered Revenue: 2021-2023

Historic Non-Current Deffered Revenue for Spyre Therapeutics (SYRE) over the last 2 years, with Jun 2023 value amounting to $2.3 million.

  • Spyre Therapeutics' Non-Current Deffered Revenue fell 1.31% to $2.3 million in Q2 2023 from the same period last year, while for Jun 2023 it was $2.3 million, marking a year-over-year decrease of 1.31%. This contributed to the annual value of $2.2 million for FY2022, which is 79.05% up from last year.
  • According to the latest figures from Q2 2023, Spyre Therapeutics' Non-Current Deffered Revenue is $2.3 million, which was down 0.00% from $2.3 million recorded in Q1 2023.
  • In the past 5 years, Spyre Therapeutics' Non-Current Deffered Revenue registered a high of $2.4 million during Q2 2022, and its lowest value of $740,000 during Q1 2022.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $2.2 million (2021), whereas its average is $2.0 million.
  • As far as peak fluctuations go, Spyre Therapeutics' Non-Current Deffered Revenue plummeted by 67.46% in 2022, and later surged by 216.35% in 2023.
  • Quarterly analysis of 3 years shows Spyre Therapeutics' Non-Current Deffered Revenue stood at $1.2 million in 2021, then surged by 79.05% to $2.2 million in 2022, then fell by 1.31% to $2.3 million in 2023.
  • Its Non-Current Deffered Revenue was $2.3 million in Q2 2023, compared to $2.3 million in Q1 2023 and $2.2 million in Q4 2022.